Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain

Pharmacology, Toxicology and Pharmaceutical Science

• Cannabinoid 100%
• Neuropathic Pain 100%
• Cannabinoid 2 Receptor 100%
• Cannabinoid 1 Receptor 60%
• Receptor 40%
• Mouse 30%
• Cannabinoid 2 Receptor Agonist 20%
• Cannabinoid Receptor 20%
• Inverse Agonist 10%
• Indole 10%
• Adverse Event 10%
• Paclitaxel 10%
• Radioligand 10%
• Mitogen Activated Protein Kinase 1 10%
• Mitogen Activated Protein Kinase 3 10%
• Cyclic AMP 10%
• Sulfur 35 10%
• Tactile Allodynia 10%
• Guanosine Triphosphate 10%

Neuroscience

• Cannabinoid 100%
• Cannabinoid 2 Receptor 100%
• Neuropathic Pain 100%
• Agonist 58%
• Cannabinoid 1 Receptor 50%
• Eicosanoid Receptor 33%
• Cannabinoid Receptor 16%
• In Vitro 16%
• Central Nervous System 8%
• Locomotor Activity 8%
• In Vivo 8%
• Adverse Effect 8%
• Guanosine Triphosphate 8%
• Cyclic Adenosine Monophosphate 8%
• Paclitaxel 8%
• Extracellular Signal-Regulated Kinases 8%
• Radioligand 8%
• Allodynia 8%